[Idiopathic haemochromatosis. I. Clinical, biological and therapeutic aspects (author's transl)].
Over the last few years the study of idiopathic haemochromatosis has not brought to light any basic change in the overall pattern of organic and metabolic damage produced by the disease and comprising altered skin pigmentation, liver disease, diabete mellitus, heart disease, endocrine dysfunction, bone and joint disease. Nevertheless, certain facets of the clinical picture have been described and progress has been made in understanding the signs of the disease. Although the desferrioxamine test is no without merit, especially if performed after vitamin C administration, for measuring the extent of iron overload, two methods seem better equipped: serum ferritin radioimmunoassay and measurement of iron concentration in a liver biopsy specimen. The HLA antigen A3 and, more especially, haplotype A3, B14, are markers for the genetic basis of the disease. Repeated phlebotomy therapy generally brings about symptomatic improvement and a significant increase in survival.
D001815:Bloodletting; D001847:Bone Diseases / Q000209:etiology; D009202:Cardiomyopathies / Q000209:etiology; D003676:Deferoxamine; D003920:Diabetes Mellitus / Q000209:etiology; D005260:Female; D005293:Ferritins / Q000097:blood; D006680:HLA Antigens / Q000032:analysis; D006432:Hemochromatosis / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D006529:Hepatomegaly / Q000209:etiology; D006801:Humans; D007006:Hypogonadism / Q000209:etiology; D007501:Iron / Q000032:analysis; D007592:Joint Diseases / Q000209:etiology; D008099:Liver / Q000473:pathology; D008297:Male; D008548:Melanosis / Q000209:etiology; D008875:Middle Aged; D012867:Skin / Q000473:pathology
D006680:HLA Antigens; D005293:Ferritins; D007501:Iron; D003676:Deferoxamine
Hémochromatose idiopathique. I. Aspects cliniques, biologiques et thérapeutiques.